Biora Therapeutics, Inc. (BIOR)
Biora Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $0.22, up 0.00% on the session, giving a market capitalisation of $994,994. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -3102875.0%. Its beta of 1.28 implies it has historically moved more than the broad market.
Biora Therapeutics, Inc. is a biotechnology company focused on developing cutting-edge oral biotherapeutic solutions. The company's core efforts involve two main therapeutic programs: Targeted Therapeutics: This program utilizes an advanced ingestible smart capsule designed to deliver medications precisely within the gastrointestinal (GI) tract. The aim is to significantly improve therapies for inflammatory bowel diseases. Systemic Therapeutics: Through a specialized ingestible capsule, this initiative provides a needle-free method for administering biotherapeutics directly into the intestinal lining, thereby promoting more effective systemic absorption throughout the body. Furthermore, Biora is actively developing diagnostic devices. These tools are engineered to better characterize the digestive system and identify various GI conditions, such as small intestine bacterial overgrowth, by offering on-site diagnosis. Originally established in 2010 as Progenity, Inc., the company rebranded to Biora Therapeutics, Inc. in April 2022. This name change was made to reflect its concentrated strategic shift towards its therapeutics pipeline. Biora Therapeutics, Inc. is headquartered in San Diego, California.
Biora Therapeutics, Inc. is most often compared with the following Healthcare names: